Loading...
Olink Holding AB (publ)
OLK•NASDAQ
Healthcare
Medical - Diagnostics & Research
$26.08
$0.08(0.31%)

Financial performance has remained strong, with revenue growing from $29.44M in Q2 2023 to $28.59M in Q1 2024. Gross profit continued to perform well, with margins at 61% in the latest quarter. Operating income reached -$26.23M in Q1 2024, holding a steady -92% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$20.89M. Net income dropped to -$15.97M, keeping EPS at -$0.13. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan